Loading...
Loading...
According to a research report published by Oppenheimer, Biogen Idec Inc.
BIIB has complied with a FDA mandated label update.
“With the addition of JCV as a risk factor, we believe Tysabri's label addresses the most concerning PML risk factor. Together with the commercial availability of the test, we expect substantially greater JCV testing in the US MS patient population, and higher numbers of known JCV-negative pts,” Oppenheimer commented.
Oppenheimer maintains its Outperform rating and $127.00 PT on Biogen Idec Inc., which closed Friday at $118.14.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in